October 19, 2026

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

Tempus: Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today...

recent articles

Number of patients eligible for genome-driven oncology therapy is increasing, but the percentage who reportedly benefit from the therapy remains at less than 5% Advances in precision medicine in oncology (precision oncology) are fueling...

Dear Reader, This is a survey to better understand the drivers for AI in Digital Pathology and what you consider to be the key enablers/blockers to adoption. We have created a short list of questions and the survey will not take more than...

New technical partnership sees DeePathology’s AI-based Helicobacter Pylori Decision Support System integrated into Inspirata’s digital pathology workflow solution, Dynamyx™. London, UK  — Cancer informatics and digital pathology...

Computational pathology is a widely used term nowadays, but its exact meaning is often subject to interpretation. For us at Ibex Medical Analytics, it’s all about the smart use of algorithms and computing power to better diagnose diseases,...

New Software Application Quantifies Changes in Dendritic Spine Morphology Over Time Williston, VT — The ability to track the changes that occur in dendritic spine morphology over time is critical to many scientific studies, which is why...

OR

platinum partners

gold partners

Silver Partners

Media Partners